US2259698A
(en)
|
1938-05-07 |
1941-10-21 |
Rare Chemicals Inc |
Physiologically effective substance and process of preparing same
|
US2594323A
(en)
|
1948-07-22 |
1952-04-29 |
Upjohn Co |
24-substituted delta 5-cholene-3, 24-diols
|
US3079385A
(en)
|
1961-01-24 |
1963-02-26 |
Roussel Uclaf |
Novel process of preparation of polyhydroxylated pregnanes
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
JPS5324071B2
(en)
|
1974-04-30 |
1978-07-18 |
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
CH628907A5
(en)
|
1975-10-10 |
1982-03-31 |
Hoffmann La Roche |
Process for the preparation of 24,25-dihydroxycholesterol derivatives
|
JPS5840960B2
(en)
|
1976-12-28 |
1983-09-08 |
帝人株式会社 |
Interconversion method between hydroxycholesterol stereoisomers
|
JPS54163565A
(en)
|
1978-06-09 |
1979-12-26 |
Teijin Ltd |
24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
|
JPS5735597A
(en)
|
1980-08-13 |
1982-02-26 |
Teijin Ltd |
25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
|
JPS61254599A
(en)
|
1985-05-07 |
1986-11-12 |
Sumitomo Pharmaceut Co Ltd |
Fluorine derivative of cholesterol
|
JPS62187485A
(en)
|
1986-02-13 |
1987-08-15 |
Teijin Ltd |
Production of 24,25-epoxycholesterol or such
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
AU698834B2
(en)
|
1993-05-24 |
1998-11-12 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
IL110309A0
(en)
|
1993-07-15 |
1994-10-21 |
Univ Kentucky Res Found |
A method of protecting against neuron loss
|
DE4338316A1
(en)
|
1993-11-10 |
1995-05-11 |
Jenapharm Gmbh |
New steroids with radicallyophilic substituents, process for their preparation and medicaments containing these compounds
|
JP4066272B2
(en)
|
1994-02-14 |
2008-03-26 |
ユーロ‐セルティック エス. ア. |
Androstanes and pregnanes for allosteric modulation of GABA receptors
|
TW385308B
(en)
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
US5595996A
(en)
|
1994-10-25 |
1997-01-21 |
Merck & Co., Inc. |
7-substituted 4-aza cholanic acid derivatives and their use
|
ES2155543T3
(en)
|
1994-11-23 |
2001-05-16 |
Cocensys Inc |
ANDROSTAN AND PREGNAN SERIES FOR ALLOSTERIC MODULATION OF THE GABA RECEIVER.
|
JPH08268917A
(en)
|
1995-03-31 |
1996-10-15 |
D D S Kenkyusho:Kk |
Antitumor agent having high transition to cancer tissue
|
KR19990022323A
(en)
|
1995-06-06 |
1999-03-25 |
씨. 랜 낸시 |
Neuroactive steroids in Andros and Pregnan series
|
US5792635A
(en)
|
1995-06-07 |
1998-08-11 |
Magainin Pharmaceuticals, Inc. |
Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
|
US6645953B2
(en)
|
1995-06-23 |
2003-11-11 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
WO1997000884A1
(en)
|
1995-06-23 |
1997-01-09 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
EP0840612A1
(en)
|
1995-07-24 |
1998-05-13 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
JPH09328498A
(en)
|
1996-06-10 |
1997-12-22 |
Teijin Ltd |
Production of 24,25-dihydroxycholesterol and its synthetic intermediate
|
WO1998005337A1
(en)
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
DE19635525A1
(en)
|
1996-08-20 |
1998-02-26 |
Schering Ag |
New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
|
JP2002514621A
(en)
|
1998-05-11 |
2002-05-21 |
ノボ ノルディスク アクティーゼルスカブ |
Substituted guanidines and diaminonitroethenes, their preparation and use
|
KR20010043558A
(en)
|
1998-05-13 |
2001-05-25 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
Meiosis regulating compounds
|
US8541600B2
(en)
|
1998-11-24 |
2013-09-24 |
Harbor Therapeutics, Inc. |
11-aza, 11-thia and 11-oxa sterol compounds and compositions
|
DE19917930A1
(en)
|
1999-04-15 |
2000-10-19 |
Schering Ag |
Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
|
US6376530B1
(en)
|
1999-05-10 |
2002-04-23 |
Merck & Co., Inc. |
Cyclic amidines useful as NMDA NR2B antagonists
|
GB9910934D0
(en)
|
1999-05-11 |
1999-07-14 |
Res Inst Medicine Chem |
Chemical compounds
|
CN1098273C
(en)
|
1999-11-12 |
2003-01-08 |
中国科学院上海有机化学研究所 |
High-stereoselectivity synthesization of 24R,25- and 24S, 25-dihydroxysteroid
|
GB0000228D0
(en)
|
2000-01-06 |
2000-03-01 |
Phytopharm Plc |
Fluoro substituted sapogenins and their use
|
GB0019290D0
(en)
|
2000-08-04 |
2000-09-27 |
Symphar Sa |
Methods for inducing apolipoprotein E secretion
|
GR1003861B
(en)
|
2000-12-29 |
2002-04-11 |
|
Novel gabaa modulating neurosteroids
|
GB0107822D0
(en)
|
2001-03-28 |
2001-05-23 |
Phytopharm Plc |
Sapogenin derivatives their synthesis and use methods based upon their use
|
PT1392713E
(en)
|
2001-05-03 |
2008-01-25 |
Univ Chicago |
Liver x receptor agonists
|
US20070197484A1
(en)
|
2001-05-03 |
2007-08-23 |
Ching Song |
Method of treating disorder related to high cholesterol concentration
|
EP1450816A4
(en)
|
2001-11-08 |
2008-02-13 |
Univ Chicago |
Method of treating disorder related to high cholesterol concentration
|
AU2002360489A1
(en)
|
2001-12-07 |
2003-06-23 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
CN102727501A
(en)
|
2002-03-27 |
2012-10-17 |
菲特法姆股份有限公司 |
Uses of sapogenins and their derivatives
|
PE20040306A1
(en)
|
2002-03-27 |
2004-05-29 |
Phytopharm Plc |
THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES
|
GB0216621D0
(en)
|
2002-07-17 |
2002-08-28 |
Imaging Res Solutions Ltd |
Imaging compounds
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
AU2003291074A1
(en)
|
2002-11-22 |
2004-06-18 |
Merck & Co., Inc. |
2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as NR2B receptor antagonists
|
AU2003288231A1
(en)
|
2002-12-13 |
2004-07-09 |
Bayer Healthcare Ag |
Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
|
FR2850023B1
(en)
|
2003-01-17 |
2007-04-06 |
Mapreg |
DRUGS FOR THE NERVOUS SYSTEM
|
GB0403889D0
(en)
|
2004-02-21 |
2004-03-24 |
Univ Edinburgh |
Uses of er-beta modulators
|
US8604011B2
(en)
*
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US20070032464A1
(en)
|
2004-10-08 |
2007-02-08 |
Shutsung Liao |
Methods of treating cancers
|
AU2005302452B2
(en)
|
2004-11-01 |
2010-12-09 |
Seo Hong Yoo |
Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
|
EP1993558B1
(en)
|
2006-02-27 |
2014-07-30 |
The Regents of The University of California |
Oxysterol compounds and the hedgehog pathway
|
CN101164540A
(en)
|
2006-08-03 |
2008-04-23 |
中山大学 |
Application of marine steroids compound in preparing medicine for treating neuronal damage
|
GB0619860D0
(en)
|
2006-10-06 |
2006-11-15 |
Birkeland Innovasjon As |
Treatment of insulin resistance and disorders associated therewith
|
US8273747B2
(en)
|
2006-11-02 |
2012-09-25 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
BR122013033954B8
(en)
|
2006-11-21 |
2021-05-25 |
Umecrine Ab |
new steroids exhibiting water solubility and resistance against increased metabolism, and methods for their production
|
US8383823B2
(en)
|
2007-06-20 |
2013-02-26 |
Auspex Pharmaceuticals |
Substituted N-aryl pyridinones
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
US20110118353A1
(en)
|
2007-11-06 |
2011-05-19 |
N. V. Organon |
Method of hormone suppression in humans
|
US9526737B2
(en)
|
2007-12-03 |
2016-12-27 |
The Regents Of The University Of California |
Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
|
WO2009090063A1
(en)
|
2008-01-16 |
2009-07-23 |
Jado Technologies Gmbh |
Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
|
WO2009094279A1
(en)
|
2008-01-25 |
2009-07-30 |
Merck & Co., Inc. |
Quinolizidinone m1 receptor positive allosteric modulators
|
AU2009244082A1
(en)
|
2008-05-09 |
2009-11-12 |
Emory University |
NMDA receptor antagonists for the treatment of neuropsychiatric disorders
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
WO2010075282A1
(en)
|
2008-12-22 |
2010-07-01 |
University Of Washington |
Molecular inhibitors of the wnt/beta-catenin pathway
|
US8822462B2
(en)
|
2009-01-28 |
2014-09-02 |
Emory University |
Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
|
EP2459581A4
(en)
|
2009-07-29 |
2012-12-26 |
Univ Chicago |
Liver x receptor agonists
|
WO2011028794A2
(en)
|
2009-09-01 |
2011-03-10 |
Lazarus Therapeutics, Inc. |
Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
|
FR2953138B1
(en)
|
2009-12-02 |
2015-10-16 |
Assist Publ Hopitaux Marseille |
AMINOSTEROIDAL COMPOUNDS FOR LOCAL TOPICAL APPLICATION FOR CUTANEO-MUCOUS DECOLONIZATION OF STAPHYLOCOCCUS AUREUS
|
WO2011092127A1
(en)
|
2010-01-26 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft |
14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
|
KR101692275B1
(en)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
Secondary structure stabilized nmda receptor modulators and uses thereof
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201008047D0
(en)
|
2010-05-14 |
2010-06-30 |
Ge Healthcare Ltd |
Method of synthesis
|
US20120035156A1
(en)
|
2010-08-09 |
2012-02-09 |
Daniela Alberati |
Combination of glyt1 compound with antipsychotics
|
US8969525B2
(en)
|
2010-11-09 |
2015-03-03 |
Enzo Life Sciences, Inc. |
Hydroxycholesterol immunoassay
|
US20150031655A1
(en)
|
2011-04-15 |
2015-01-29 |
University Of North Dakota |
Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
|
US20140335050A1
(en)
|
2011-05-27 |
2014-11-13 |
The General Hospital Corporation |
Methods, compositions, and kits for the treatment of cancer
|
JP2014521662A
(en)
|
2011-07-29 |
2014-08-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Novel 17β-heteroaryl substituted steroids as modulators of GABAA receptors
|
BR112014005373B1
(en)
*
|
2011-09-08 |
2022-04-19 |
Sage Therapeutics, Inc |
Neuroactive steroid compounds, compositions and uses thereof
|
ME03372B
(en)
|
2011-10-07 |
2020-01-20 |
Takeda Pharmaceuticals Co |
1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
|
CN108976272B
(en)
*
|
2011-10-14 |
2021-05-25 |
萨奇治疗股份有限公司 |
3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof
|
US20150119327A1
(en)
|
2012-04-25 |
2015-04-30 |
The Regents Of The University Of California |
Drug screening platform for rett syndrome
|
US9737522B2
(en)
|
2012-08-09 |
2017-08-22 |
Emory University |
NMDA receptor modulators and uses related thereto
|
US9630986B2
(en)
|
2012-12-18 |
2017-04-25 |
Washington University |
Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
|
US20150376225A1
(en)
|
2013-01-23 |
2015-12-31 |
Sphaera Pharma Pvtd. Ltd. |
Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
|
SG11201505934XA
(en)
|
2013-01-29 |
2015-09-29 |
Naurex Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
EP3865135A3
(en)
*
|
2013-03-13 |
2021-11-03 |
Sage Therapeutics, Inc. |
Neuroactive steroids for use in therapy
|
DK3461834T3
(en)
|
2013-03-13 |
2021-08-23 |
Sage Therapeutics Inc |
NEUROACTIVE STEROIDS
|
ES2751457T3
(en)
|
2013-09-25 |
2020-03-31 |
Van Andel Res Institute |
Highly potent glucocorticoids
|
EP4306114A1
(en)
|
2014-06-18 |
2024-01-17 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
US10238664B2
(en)
|
2014-07-09 |
2019-03-26 |
Duke University |
Compositions and methods for the repair of myelin
|
KR20170065637A
(en)
|
2014-10-07 |
2017-06-13 |
세이지 테라퓨틱스, 인크. |
Neuroactive compounds and methods of use thereof
|
MD3319612T2
(en)
|
2015-07-06 |
2021-10-31 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
RU2744267C2
(en)
|
2015-07-06 |
2021-03-04 |
Сейдж Терапьютикс, Инк. |
Oxysteroles and methods of using them
|
AU2016289965B2
(en)
|
2015-07-06 |
2021-09-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
GB2557875A
(en)
|
2015-09-02 |
2018-07-04 |
Univ Swansea |
Diagnostic methods and kits
|
JP7112331B2
(en)
|
2016-04-01 |
2022-08-03 |
セージ セラピューティクス, インコーポレイテッド |
Oxysterols and their uses
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
PL3481846T3
(en)
|
2016-07-07 |
2021-12-20 |
Sage Therapeutics, Inc. |
11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
|
EP3481844B1
(en)
|
2016-07-11 |
2024-04-17 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
PT3519422T
(en)
|
2016-09-30 |
2022-12-05 |
Sage Therapeutics Inc |
C7 substituted oxysterols and methods as nmda modulators
|
IL266093B2
(en)
|
2016-10-18 |
2024-02-01 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
MA46565A
(en)
|
2016-10-18 |
2019-08-28 |
Sage Therapeutics Inc |
OXYSTEROLS AND THEIR METHODS OF USE
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
IL271343B2
(en)
|
2017-06-23 |
2023-12-01 |
Intercept Pharmaceuticals Inc |
Methods and intermediates for the preparation of bile acid derivatives
|
WO2019094724A1
(en)
|
2017-11-10 |
2019-05-16 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating genetic epileptic disoders
|
TW202110824A
(en)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
Compounds, compositions, and methods of use
|